It seems that the time of the rally in pharmaceutical stocks is out. But this is only at first glance. There are excellent investment ideas in particular securities. 

For example, AbbVie, a biopharmaceutical company in the USA, which is engaged in a lot of research and development. After the separation from Abbott Laboratories, there were doubts about the sustainability of the business, but already in 2020, with the acquisition of Allergan, AbbVie’s positions became stronger. The main bet is on medicines to fight hepatitis C, arthritis, HIV, Parkinson’s disease, etc. 

Strengths:

• probable profit growth by 10-12% following the results of the II-IV quarters against the background of active promotion of drugs;
• attractive dividend yield;
• multipliers that are more stable than those of competitors Merck and Pfizer;
• absence of direct link with Abbott and negative information related to problems in the production of formula.

Risks:

• continuation of broad sales on the US stock market, which can pull the stock prices down by inertia;
• negative corporate news. 

It is worth noting that in this case, the risks are the same for almost all US securities. 

The technical picture of ABBV trading suggests a local increase to $170 per share at today’s price of $154. 

The MACD indicator develops growth in the neutral zone and strengthens the buy signal. The Stochastic oscillator has entered the overbought zone and signals a purchase.